

TO: OMOP Extended Consortium Stakeholder

FROM: Thomas Scarnecchia
Executive Director, Observational Medical Outcomes Partnership
tscarnecchia@fnih.org

Observational Medical Outcomes Partnership Research Investigators:
Abraham G. Hartzema PharmD, MSPH, PhD, FISPE
Marc Overhage, MD, PhD
Judith A. Racoosin, MD, MPH
Paul Stang, PhD
Patrick Ryan, MEng

SUBJECT: Establishment of the OMOP Extended Consortium
Web Meeting scheduled for April 22, 2010 at 11:00 am EDT.

DATE: April 9, 2010

We would like to invite you to the *OMOP Extended Consortium* meeting, which will be held via a web conference on April 22, 2010 at 11:00 am EDT.

OMOP is a public-private partnership designed to improve the monitoring of drugs for safety and effectiveness. The partnership is conducting a two-year research initiative to determine whether it is feasible and useful to use automated healthcare data to identify and evaluate safety issues of drugs on the market. The Partnership's methodological research is conducted across multiple disparate observational databases (administrative claims and electronic health records). The series of studies being conducted include assessing different types of automated healthcare data, developing tools and methods to analyze the databases, and evaluating how analyses can contribute to decision-making.

OMOP relies on the expertise and resources of the U.S. Food and Drug Administration, other federal agencies, academic institutions, the pharmaceutical and health insurance industries and non-profit organizations. A network of institutions, managed by the Foundation for the National Institutes of Health, carries out specific OMOP tasks, and all together, more than 100 partners are collaborating. Throughout the work phases of OMOP all work products are made publicly available to promote transparency and consistency in research.

The OMOP Research Team is actively developing and applying a variety of methods and tools across multiple disparate observational data sources within the OMOP community. We would like to invite additional organizations to conduct complementary research to assess how these methods perform within other environments. The OMOP Extended Consortium has been established to engage interested groups from industry, government, academia, payers, healthcare organizations, and other stakeholders, who would like to voluntarily participate in our methodological research to inform the appropriate use of observational data for active drug safety surveillance. OMOP Extended Consortium members will be recognized as part of the OMOP research community, and will have the opportunity to contribute findings and share learnings with the OMOP research team.

The OMOP Extended Consortium meeting will include an update from the OMOP Research team about the progress to date, and a discussion about the opportunities for participating in the research plan as part of the OMOP Extended Consortium. We are very excited to commence the OMOP Extended Consortium and hope that you can join the April meeting. We look forward to your attendance and participation. If you have any questions, please do not hesitate to contact us.

OMOP EXTENDED CONSORTIUM MEETING

DATE: April 22, 2010

TIME: 11:00 am – 12:00 pm EDT

To register for this meeting, please click the following link to see more information, and to register.
<https://meetings.webex.com/meetings/j.php?ED=9001392&RG=1&UID=489919782>

Once you have registered, you will receive an email message confirming your registration.
This message will provide the information that you need to join the meeting.

REGISTRATION DEADLINE: April 20, 2010

Any questions, please notify Emily Welebob, OMOP Research Manager, ewelebob@fnih.org